- Description:
-
A meta-analysis comparing injectable and oral PCSK9i therapies, including the emerging oral agent MK-0616, found comparable LDL-C reductions across all drug classes. Notably, oral formulation may improve treatment adherence due to needle aversion,...
- Date:
-
April 15, 2025